Healthy Skepticism Library item: 11923
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Garber AM, McClellan MB.
Satisfaction guaranteed - 'payment by results' for biologic agents.
N Engl J Med 2007 Oct 18; 357:(16):1575-7
http://content.nejm.org/cgi/content/extract/357/16/1575
Abstract:
As increasing numbers of promising but expensive biologic agents are introduced for use as medical treatments, drug pricing has become a high-profile issue. Earlier this year, pricing practices took a new turn in Britain, when the National Institute for Health and Clinical Excellence (NICE), the evaluative agency that applies cost-effectiveness analysis in making recommendations concerning drug coverage, declined to support coverage of the proteasome inhibitor bortezomib (Velcade) by the British National Health Service (NHS) for the treatment of multiple myeloma. It concluded that the price was too high relative to NICE’s estimates of its average benefits for the population to . . .
Keywords:
MeSH Terms:
Biological Products/economics*
Biological Products/therapeutic use
Boronic Acids/economics
Drug Approval/economics
Drug Costs*
Drug Industry/economics*
Great Britain
Humans
Pyrazines/economics
Quality Assurance, Health Care
Reimbursement Mechanisms*
State Medicine
Substances:
Biological Products
Boronic Acids
Pyrazines
bortezomib
